News—
Drugging WRN in MSI-H Cancers.
bit.ly/3VVy6sJ

9 days left! Any questions feel free to DM or email me.

Dream team!!

Whether or not you're at the #AACR24 minisymposium on experimental and molecular therapeutics right now, read the hot-off-the press Cancer Discovery paper by speaker Gabriele Picco, Garnett Lab, and colleagues describing novel Werner helicase inhibitors👇🏼aacrjournals.org/cancerdiscover…

Just published with the #AACR24 presentation in the Novel Antitumor Agents session— Novel WRN Helicase Inhibitors Selectively Target Microsatellite Unstable Cancer Cells.
bit.ly/3VRrhYW
Gabriele Picco Mathew Garnett Garnett Lab Wellcome Sanger Institute AACR

A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization - a study by Wellcome Sanger Institute Garnett Lab, Francesco Iorio & colleagues in Cancer Cell #AACR24 hubs.li/Q02rwTDY0

It's finally organoids day at #AACR24 !! Join us for the AT05 session at 12:30pm in Ballroom CD to see how we use tumor organoids for immunooncology, for rare tumors modeling and precision medicine, for undestanding tumor dependencies
abstractsonline.com/pp8/#!/20272/s…

Big couple of days for the team at #AACR24 . Mathew Garnett will be presenting *today* on the development of an organoid biobank for dependency mapping. Ballroom 20CD at 13:25. Also, don't miss Gabriele Picco tomorrow presenting novel WRN helicase inhibitors.

Cool new tech for dual-guide CRISPR-Cas9 KO screens from talented Andrew Bassett and team Wellcome Sanger Institute. Single-step cloning, balanced sgRNA expression, low swaps, and all with validated spCas9 system. A great collaboration and a pleasure to work with such a talented group.

Great to see this out! Dual-guide CRISPR screening Wellcome Sanger Institute Andrew Bassett Garnett Lab

Congratulations 🥳